These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 14602061

  • 1. Optimizing immunomodulator therapy for inflammatory bowel disease.
    Dubinsky MC.
    Curr Gastroenterol Rep; 2003 Dec; 5(6):506-11. PubMed ID: 14602061
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
    Spencer E, Norris E, Williams C, Dubinsky MC.
    Inflamm Bowel Dis; 2019 Jan 01; 25(1):142-149. PubMed ID: 29920603
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M, Theede K, Nielsen AM.
    Ugeskr Laeger; 2014 May 26; 176(22):. PubMed ID: 25352005
    [Abstract] [Full Text] [Related]

  • 6. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.
    Bradford K, Shih DQ.
    World J Gastroenterol; 2011 Oct 07; 17(37):4166-73. PubMed ID: 22072847
    [Abstract] [Full Text] [Related]

  • 7. [Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease].
    Gisbert JP, González-Lama Y, Maté J.
    Gastroenterol Hepatol; 2006 Nov 07; 29(9):568-83. PubMed ID: 17129552
    [Abstract] [Full Text] [Related]

  • 8. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
    Haines ML, Ajlouni Y, Irving PM, Sparrow MP, Rose R, Gearry RB, Gibson PR.
    Inflamm Bowel Dis; 2011 Jun 07; 17(6):1301-7. PubMed ID: 20812329
    [Abstract] [Full Text] [Related]

  • 9. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
    Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE, Clinical Pharmacogenetics Implementation Consortium.
    Clin Pharmacol Ther; 2011 Mar 07; 89(3):387-91. PubMed ID: 21270794
    [Abstract] [Full Text] [Related]

  • 10. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
    Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S.
    Inflamm Bowel Dis; 2006 Apr 07; 12(4):251-7. PubMed ID: 16633046
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP, Wong DR, Engels LG, Bierau J, Bakker JA, Paulussen AD, Romberg-Camps MJ, Stronkhorst A, Bus P, Bos LP, Hooymans PM, Stockbrügger RW, Neef C, Masclee AA.
    J Crohns Colitis; 2012 Jul 07; 6(6):698-707. PubMed ID: 22398098
    [Abstract] [Full Text] [Related]

  • 13. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X.
    Aliment Pharmacol Ther; 2012 Jan 07; 35(1):15-36. PubMed ID: 22050052
    [Abstract] [Full Text] [Related]

  • 14. Prevalence of TPMT polymorphism in Indian patients requiring immunomodulator therapy and its clinical significance.
    Davavala SK, Desai DC, Abraham P, Ashavaid T, Joshi A, Gupta T.
    Indian J Gastroenterol; 2014 Jan 07; 33(1):41-5. PubMed ID: 23996738
    [Abstract] [Full Text] [Related]

  • 15. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.
    Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA.
    Gastroenterology; 2002 Apr 07; 122(4):904-15. PubMed ID: 11910342
    [Abstract] [Full Text] [Related]

  • 16. Optimizing thiopurine therapy in inflammatory bowel disease.
    Chevaux JB, Peyrin-Biroulet L, Sparrow MP.
    Inflamm Bowel Dis; 2011 Jun 07; 17(6):1428-35. PubMed ID: 20949566
    [Abstract] [Full Text] [Related]

  • 17. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
    Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M.
    Clin Pharmacokinet; 2007 Jun 07; 46(3):187-208. PubMed ID: 17328579
    [Abstract] [Full Text] [Related]

  • 18. Thiopurine Methyltransferase Genetic Polymorphisms and Activity and Metabolic Products of Azathioprine in Patients with Inflammatory Bowel Disease.
    Pashazadeh P, Marjani A, Asadi J, Khoshnia M.
    Endocr Metab Immune Disord Drug Targets; 2019 Jun 07; 19(4):541-547. PubMed ID: 30451123
    [Abstract] [Full Text] [Related]

  • 19. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Müller R, Schwab M.
    Ther Drug Monit; 2007 Feb 07; 29(1):1-5. PubMed ID: 17304143
    [Abstract] [Full Text] [Related]

  • 20. The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease.
    Chisick L, Oleschuk C, Bernstein CN.
    Can J Gastroenterol; 2013 Jan 07; 27(1):39-43. PubMed ID: 23378982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.